Navigation Links
NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
Date:12/2/2009

Forward-Looking Statements

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding clinical trials and development of the 2009 H1N1 vaccine, the potential use of any data from clinical trials and other anticipated milestones in Mexico and other countries, including the U.S. and the E.U., are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including full and complete clinical trial results, which may not be sufficient for regulatory approval in Mexico or may indicate safety concerns not yet encountered; even if the subset results reported today or other final and complete results of the planned clinical trial are positive, the data may not be accepted by regulatory bodies in the U.S., the E.U. or other countries or the 2009 H1N1 vaccine may not be approved by the Mexican government or additional clinical trials may be required; if approved by the Mexican government, approval of the 2009 H1N1 vaccine may not be timely and thus may not be granted until after the 2009/2010 influenza season has ended; sales of the 2009 H1N1 vaccine are not scheduled to begin in Mexico until late in the 2009/2010 influenza season which could result in poor sales; Avimex is expected to be responsible for sales of the 2009 H1N1 vaccine in Mexico, thus, the Company would be dependent on Avimex's sales effort; Xcellerex, a third party manufacturer engaged to produce commercial quantities of the 2009 H1N1 vaccine, has not manufactured the Company's 2009 H1N1 vaccine at commercial levels and the
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... EASTON, Mass. , Sept. 19, 2014 /PRNewswire/ ... "Company") today announced it has received and approved ... Barozyme HT48 instruments and has begun to manufacture ... the first instrument will be ready for shipment ... be built and released at a rate of ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... collagenase-based products marketed as XIAFLEX ® in the U.S. ... BioSpecifics, President, Tom Wegman , will present a corporate ... the Biotech Industry Conference. The presentation will ... EDT at the Millennium Broadway Hotel in New ...
(Date:9/19/2014)... -- Aufgrund der enormen Nachfrage seines ... aktualisiert, der jetzt auch die Jahre 2014 - ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und den ... Für international tätige Unternehmen geht es ... sondern darum, "wann" sie die neu in Kraft ...
Breaking Medicine Technology:Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 2Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
(Date:9/19/2014)... 19, 2014 Follow us on ... the medical imaging market, are engineered to enhance the ... the past three decades have expanded the application roles ... iodine based agents used for over half a century ... imaging agents have witnessed sea changes, revolutionizing in the ...
(Date:9/19/2014)... 19, 2014 The ... Scandinavian style of eating, is making its ... Diet Doc’s medical weight loss ... eating good food which leads to improved ... teaching patients to understand how diet can ...
(Date:9/19/2014)... 19, 2014 Recent financial data ... industry increased their sales by 7% in the last ... trucking industry can be used as a bellwether to ... whole. This data has been proven to show trends ... freight transportation. Other non-trucking data is largely influenced by ...
(Date:9/19/2014)... MD & Salt Lake City, UT (PRWEB) September 19, ... to launch the new Activz Greens Smoothie ... Products Expo East, September 18th-20th in Baltimore, MD. ... with 8 organic super foods combined in one convenient ... Natural Products Expo East, September 18th-20th in Baltimore, MD. ...
(Date:9/19/2014)... Prussia, PA (PRWEB) September 19, 2014 ... Business Process Outsourcing solutions for Health Plans in ... Medicaid markets, will sponsor a Networking Breakfast Session ... the Health Industry Advisory Practice at Pricewaterhouse Coopers, ... at the AHIP’s 2014 National Conference on Medicare ...
Breaking Medicine News(10 mins):Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 2Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 3Health News:New Clinical Applications and Advanced Imaging Capabilities Drive Growth in the Imaging Agents Market, According to New Report by Global Industry Analysts, Inc. 4Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 2Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 3Health News:Diet Doc’s Medical Weight Loss Programs Announce Diet Plans Based on the Same Principles as the New Nordic Diet 4Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 2Health News:LeaseQ Announces Good News For The Truck Leasing Industry As Truck Rentals In The U.S Continues to Gain Traction 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 2Health News:TMG Health To Sponsor Pricewaterhouse Coopers Speaker at AHIP’s National Conference on Medicare 3
... CORONA, Calif., Feb. 19 Watson Pharmaceuticals,Inc. (NYSE: ... branded pharmaceuticals,today reported financial results for its fourth quarter ... Fourth Quarter 2008 Results , ... increased $17.9 million or 3,percent from the fourth quarter ...
... to Vote Gold Card and Reject Dissidents, Director Slate ... (Nasdaq: LCAV ) today announced that it ... it urges support for Company management and its Board ... letter follows: To My Fellow Stockholders:Your LCA-Vision executive Team ...
... Full-Year 2009 OutlookVIRGINIA BEACH, Va., Feb. 19, 2009 AMERIGROUP ... net income for the fourth quarter of 2008 increased 20.0% ... income of $31.1 million, or $0.57 per diluted share, for ... December 31, 2008, the Company,s net loss was $50.7 million, ...
... foundation, announces its series of dental related health care reports under ... ... Springs, CO (PRWEB) February 19, 2009 -- Toxic Elements Research Foundation ... related health care reports under the title of ,Elements of Disease., ...
... greenhouse gas emissions, Oregon will face some $3.3 billion ... tab of about 4 percent of annual household income ... University of Oregon,s Climate Leadership Initiative,s Program on Climate ... Economics is guided by a steering committee of 19 ...
... Sessions begin Saturday, March 14 at 10 a.m. SAN FRANCISCO, ... and Wellness Center , is excited to bring back its ... San Francisco. Starting Saturday, March 14 at 10 a.m., ... Park or in the Presidio (near the Lyon Street Stairs) ...
Cached Medicine News:Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 2Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 3Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 4Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 5Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 6Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 7Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 8Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 9Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 10Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 11Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 12Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 13Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 14Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 15Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 16Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 17Health News:Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook 18Health News:LCA-Vision Reports Tangible Results from Business Strategy 2Health News:LCA-Vision Reports Tangible Results from Business Strategy 3Health News:LCA-Vision Reports Tangible Results from Business Strategy 4Health News:LCA-Vision Reports Tangible Results from Business Strategy 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 2Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 3Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 4Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 5Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 6Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 7Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 8Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 9Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 10Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 11Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 12Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 13Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 14Health News:AMERIGROUP Reports Q4 Net Income of $37.3 Million or $0.70 Per Diluted Share 15
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: